According to the model, the maximum tolerated dose of 2.5 mg twice a day dosing, GSK2126458 would likely provide enough exposure to significantly impact on the key PD endpoints, including Akt phosphorylation and fibroblast proliferation in the lungs of patients with IPF (table 1). Here, AKT1 is linked to idiopathic pulmonary fibrosis.